September 3rd, 2020 | 13:50 CEST
HAEMATO, MBH Corporation, USU Software - on the right path in 2020
Table of contents:
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
Sales and earnings growth achieved
HAEMATO AG is a listed specialty pharma company and focuses on growth markets of off-patent and patent-protected drugs. The main focus is on the therapy areas oncology, HIV/AIDS, neurology, cardiovascular and other chronic diseases. In the fast growing market of aesthetic medicine HAEMATO AG focuses on the largest market for private patients. The demand for inexpensive medications, which are delivered in highest quality and always meet the demand for reliable and comprehensive medical care, will continue to grow in the coming years as the life expectancy of the population increases.
In the first six months of 2020, the company achieved revenue growth of 23.2% from EUR 94.01 million in the previous year to EUR 115.81 million. As a result of the recent 10:1 capital reduction, the number of shares was reduced to 2.29 million (previously: 22.87 million). In line with the new number of shares and the company's recent performance, analysts at GBC Research have slightly lowered the target price per share to EUR 49.00 (previously: EUR 5.00), but continue to assign a BUY rating.
Fifth acquisition announced in 2020
MBH Corporation PLC is an investment holding company with subsidiaries in the construction, education, leisure and healthcare sectors. The group brings together well established and profitable small companies with a buy-and-hold perspective. Most of these subsidiaries were acquired through an exchange of shares by the company owners for new MBH shares. Given the favorable interest rate environment, MBH has also recently started to make loan-financed acquisitions. One example is the acquisition of Robinson's Caravans in 2020, which will be settled with a five-year loan with a final cash payment on maturity.
For future acquisitions, GBC Research's analysts have primarily assumed that the company will be financed under the bond program, which will result in an increase in debt with a corresponding increase in financial expenses. On the other hand, this will lead to a significantly lower dilution effect. Since the number of outstanding shares has increased significantly from 49.2 million to 61.4 million, the result of the DCF model is subject to a dilution effect. Although the fair enterprise value calculated by GBC increases from GBP 83.65 million to GBP 95.11 million, the fair value per share decreases inversely from GBP 1.70 to GBP 1.55 due to the higher number of shares.
Earnings forecasts and price target raised
USU Software AG and its subsidiaries develop and sell software solutions for knowledge-based service management. Its range of services includes solutions for strategic and operational IT & enterprise service management. Customers are provided with an overall view of their IT processes and IT infrastructure and are able to plan, charge, monitor and control services transparently. In the field of software license management, USU is one of the leading manufacturers worldwide.
The USU Group's international customer base now includes over 1,000 companies, including Allianz, Baloise Group, BOSCH, BMW, Daimler, Deutsche Telekom, DEVK, EDEKA, Heidelberger Druckmaschinen, Jacobs Engineering, Jungheinrich, Poste Italiane, Texas Instruments, VW, W&W and ZDF. In the first six months of 2020, USU Software AG achieved sales growth of 16.1% from EUR 44.88 million in the previous year to EUR 52.10 million, despite the current situation characterized by the Covid-19 pandemic. The analysts of GBC Research have reacted accordingly and increased the share price target from EUR 19.15 to EUR 22.00, but still maintain their 'HOLD' rating.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.